Syn2bio S.A.

zł 62.00As of Sun 8 Nov 2026, 12:00 UTC

WSE:S2BHealthcare

Country Poland

PE (Fwd) —

TSR 10Y CAGR —

Div yield —

ROE (133.21%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap zł 541.2M

ROIC (257.63%)

SE Grade™

—

Value

—

Quality

Moat

1Y Price

Reference

zł 61

—

(2.42%)

—

TTM

FYE 30 Sep PLN

FY2023

FY2024

FY2025

FY2026E

FY2027E

Trend

10Y

Peers

◌—

Revenuezł M

—

◌—

—

Revenue growth%

—

Gross margin%

—

Operating margin%

—

Net margin%

—

P/E ratio (avg)x

—

EV/EBITx

—

(3.90)

FCF yield (avg)%

—

FCF margin%

—

0.891

FCF / Net incomex

—

1.140

1.378

0.891

—

1.140

—

(257.63)

ROIC%

—

(230.68)

(215.87)

(257.63)

—

(230.68)

—

(133.21)

Return on equity%

—

(103.69)

(107.97)

(133.21)

—

(107.97)

—

(90.29)

Return on assets%

—

(84.91)

(80.93)

(90.29)

—

(84.91)

—

(2.71)

EPSzł

—

(1.36)

(1.87)

(2.71)

—

(44.78)

EPS growth%

—

(37.94)

(44.78)

—

(41.36)

—

1.91

Bookvalue per shzł

—

1.31

2.16

1.91

20.81%

—

(2.42)

FCF per sharezł

—

(1.55)

(2.58)

(2.42)

—

Dividend per shzł

—

Div yield (avg)%

—

Payout ratio%

—

8.729

Shares (diluted)M

—

8.729

—

◌8.729

—

Buyback yield%

—

◌—

—

0.039

D/E ratiox

—

0.054

0.030

0.039

—

534.6

Enterprise valuezł M

—

534.6

—

LT debtzł M

—

Peers (US$141.7M)

Cap (US$)

Bioceltix S.A.

96.40M

—

Ryvu Therapeutics S.A.

95.99M

—

Captor Therapeutics…

86.64M

—

Biomm S.A.

142.2M

25.79x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(553.0)

(438.8)

Own earn%

—

Sh yield%

—

Owners

Insiders/Inst%

25.18

8.40

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/3

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

Op margin range%

—

$1 testx

—

Incr. ROIC%

−370

Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. It is also engages in the research of new pharmaceutical compounds and its further study, registration, and market launch as a medicinal product. Syn2bio S.A.

Revenue by segment

No breakdown available

Asset mix

Trend

Other

72.43%

Cash and investments

27.57%

Reinvestment returns

No breakdown available